$IPSC Long

IPSC Century Therapeutics, Inc. (NASDAQ: IPSC) is a biotechnology company based in Philadelphia, Pennsylvania, specializing in the development of genetically engineered allogeneic cell therapies for treating solid tumors and hematological malignancies. Their lead product candidate, CNTY-101, is an induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor (CAR)-iNK cell therapy currently in Phase 1 trials targeting CD19 for relapsed or refractory B-cell lymphoma. The company also collaborates with Bristol-Myers Squibb to develop additional iNK or iT programs.

As of February 15, 2025, Century Therapeutics' stock price is $0.7745, with an intraday high of $0.8104 and a low of $0.758. The company has a market capitalization of approximately $62.62 million. Over the past year, the stock has decreased by 83.21%. Despite this decline, four analysts have given the stock a "Strong Buy" rating, with an average 12-month price target of $11, suggesting a potential increase of over 1,400%.

Investors should consider the company's financial performance, including a 57.01% decrease in revenue in 2023 compared to the previous year, and a net loss of $136.67 million.

Given the company's focus on innovative therapies and its strategic partnerships, potential investors should weigh the high-risk nature of biotechnology investments against the potential for significant returns.